Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | ACP3 | P15309 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115844 | 0.89 | FDPS (0.34) | PPARGPPARADHODHKDM4EALOX5 | |
| SCHEMBL2117123 | 0.89 | FDPS (0.38) | PPARGPPARAMCHR1DHODHKDM4E | |
| SCHEMBL2115926 | 0.85 | MAPT (0.38) | KDM4EALOX5FDPSLMNAHPGD | |
| SCHEMBL2116390 | 0.85 | PIK3CA (0.35) | PPARGPPARADHODHFDPSLMNA | |
| SCHEMBL2116296 | 0.83 | PSMB5 (0.33) | PPARGPPARADHODHKDM4EFDPS | |
| SCHEMBL2117646 | 0.83 | PPARG (0.32) | PPARGPPARADHODHFDPS | |
| SCHEMBL2116715 | 0.83 | PPARG (0.33) | PPARGPPARADHODHFDPS | |
| SCHEMBL2118877 | 0.82 | ITK (0.33) | PPARGPPARADHODHKDM4EFDPS | |
| SCHEMBL2116250 | 0.82 | PPARG (0.35) | PPARGPPARAMCHR1DHODHKDM4E | |
| SCHEMBL2119073 | 0.81 | CNR1 (0.32) | PPARGPPARAFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | disclosed |
| EP-2250152-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | FDPS, GGPS1, CTPS1 | PPARG 1752/4885PPARA 2484/4885MCHR1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.